Results 31 to 40 of about 5,299 (209)
Higher Circulating Lymphocytes and the Incidence of Pre-eclampsia and Eclampsia
Excessive immune activation contributes to the onset of early dysfunction of the maternal-fetal interface, and it is closely linked to the development of pre-eclampsia.
Qiuping Zhao +8 more
doaj +1 more source
Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal
Pre-eclampsia and eclampsia are two hypertensive disorders of pregnancy, considered major causes of maternal and perinatal death worldwide. Pre-eclampsia is a multisystemic disease characterized by the development of hypertension after 20 weeks of ...
Gonçalo Miguel Peres +2 more
doaj +1 more source
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman +3 more
wiley +1 more source
The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model
Aims Nirmatrelvir is an effective therapeutic option for COVID‐19 infection and is often administered after symptom onset in pregnant individuals, but few data are available on the associated fetal exposure. The placental perfusion model evaluates maternal–fetal drug transfer across the human placenta and thus can determine fetal drug exposure.
Magdalene Zabek +5 more
wiley +1 more source
RISK FACTORS AND LABOUR OUTCOME IN PAROUS WOMEN WITH PRE - ECLAMPSIA [PDF]
This is a case-control study, carried out to estimate the frequency of parous women with pre-eclampsia among all deliveries conducted in the study period (September 2004 -September 2005); to identify demographic, medical and obstetrical risk factors that
Methal A. Alrubaee
doaj +1 more source
Aim To quantify the prevalence of pregnancy‐, lactation‐ and reproductive potential‐related eligibility criteria in cardiovascular clinical trials and to evaluate whether they are supported by drug‐specific safety data. Methods We analysed randomized phase 3 and phase 4 cardiovascular clinical trials registered on ClinicalTrials.gov between 1 January ...
Jera Gurakuqi +6 more
wiley +1 more source
ABSTRACT Introduction GRIA2 encodes the GluA2 ionotropic α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor subunit. Pathogenic GRIA2 variants cause epilepsy, developmental delay, and neurobehavioral disorders. Characterizations of clinical features, including seizure types and their treatments, in patients with GRIA2‐related ...
Sai Srihitha Dommata +9 more
wiley +1 more source
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian +12 more
wiley +1 more source
ABSTRACT Aspirin has been used to treat pain and fever for 120 years. Its uses expanded into treating arthritis and prevention of thrombotic events. Its anti‐cancer role emerged with observational studies in the 1980's and subsequent cancer review in those treated with aspirin in cardiovascular trials.
John Burn, D. Timothy Bishop
wiley +1 more source

